Views & Analysis ASH 2017: CAR-T therapy and beyond As the American Society of Hematology’s 2017 congress approaches, there’s plenty to be excited about – not just in blood cancer, but in previously overlooked diseases such as sickle cell anaemi
News J&J rumoured to be sizing up $12bn Genmab acquisition Speculation mounts that J&J will bid for R&D partner
News Future uncertain for Innate and BMS' troubled lirilumab Doubts over future of cancer immunotherapy
News FDA approvals expand reach of Roche's Zelboraf and Alecensa New US indications for Zelboraf and Alecensa
News Novartis files CAR-T in Europe in broader use than Gilead ri... Swiss pharma chasing EU licence in NHL and ALL indications
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
